Serum lipidomic profile may predict diabetic neuropathy much before it sets in Diabetes patients

Written By :  Dr. Kamal Kant Kohli
Published On 2022-10-04 05:15 GMT   |   Update On 2022-10-04 06:26 GMT

Diabetic neuropathy is a painful and disabling complication of diabetes. According to an estimate, out of the 37 million Americans those suffer from diabetes, up to 50% may end up with diabetic neuropathy.While some medications can reduce pain, scientists continue searching for factors that cause patients to develop diabetic neuropathy-to identify ways to reduce the risk of...

Login or Register to read the full article

Diabetic neuropathy is a painful and disabling complication of diabetes. According to an estimate, out of the 37 million Americans those suffer from diabetes, up to 50% may end up with diabetic neuropathy.While some medications can reduce pain, scientists continue searching for factors that cause patients to develop diabetic neuropathy-to identify ways to reduce the risk of harmful symptoms.

Researchers at at Michigan Medicine conducted a retrospective cohort study that examined lipidomic profiles 10 years prior to type 2 diabetic neuropathy assessment.

They found that multiple lipid biomarkers are linked to the development of neuropathy in patients with type 2 diabetes.The findings open up potential to test for biomarkers and facilitate more focused management of patients with diabetic neuropathy.

Results published in the Annals of Clinical and Translational Neurology reveal that participants with high scores for diabetic neuropathy had changes in lipids reflecting impaired energy metabolism.

Obesity and dyslipidemia are known neuropathy risk factors, suggesting lipid profiles early during type 2 diabetes may identify individuals who develop neuropathy later in the disease course.But the serum lipidomic profile associated with neuropathy in type 2 diabetes is not well understood. 

Researchers examined serum samples from nearly 70 members of the Gila River Indian community with type 2 diabetes who were tested for neuropathy 10 years later. They analyzed 435 different species of lipids, which are organic compounds composed of fats and oils.

"We have the potential to test for these lipid biomarkers in patients with type 2 diabetes to identify those with the highest risk of developing peripheral neuropathy and facilitate more focused management of those patients," said senior author Eva L. Feldman, M.D., Ph.D., James W. Albers Distinguished Professor at U-M and the Russell N. DeJong Professor of Neurology and director of the NeuroNetwork for Emerging Therapies at Michigan Medicine.

While there were differences between basic lipid profiles of participants with and without neuropathy, researchers found a pattern in blood lipid profiles 10 years prior to a person developing neuropathy that showed signaling dysfunction in a critical pathway called b-oxidation. This pathway converts lipids into sources of nerve energy, and, when impaired, energy-starved nerves undergo damage, leading to neuropathy.

"As we learn more about the relationship between serum lipid species and neuropathy, it will open up the possibility of targeted therapeutic treatment, both with drugs and lifestyle interventions," Feldman said. "Our findings support the concept that unsaturated healthy fats are a better source of energy for nerves that highly saturated fats. We strongly recommend a Mediterranean-type diet to maintain a healthy nervous system."

Feldman also advocates exercise, which increases the efficiency of the b-oxidation pathway. "Engaging in a healthy diet and exercise program is the key to preventing neuropathy," she said.

Reference:

Farsad Afshinnia, Evan L. Reynolds,Thekkelnaycke M. Rajendiran, Tanu Soni,Jaeman Byun, Masha G. Savelieff, Helen C. Looker, Robert G. Nelson, George Michailidis, Brian C. Callaghan, Subramaniam Pennathur,Eva L. Feldman, First published: 03 August 2022 https://doi.org/10.1002/acn3.51639

Tags:    
Article Source : Annals of Clinical and Translational Neurology

Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement/treatment or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2024 Minerva Medical Treatment Pvt Ltd

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News